CS1002-101
07 Dec 2020
Trial Summary
Trial Summary
A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose-Escalation and Expansion Study of the Anti-PD-1 Monoclonal Antibody CS1003 in Subjects with Advanced Solid Tumors
Acronym:
CS1002-101
ACTRN/NCT /ethics:
NCT03523819
Scientific title:
A Study of CS1002 in Subjects With Advanced Solid Tumors
Sponsor / Cooperative group:
Cstone
Trial & Patient Characteristics
| Cancer Type | All cancers |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I |
| Age Range | 18 years and older |
| Sex | Both |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced, Metastatic or Widespread |
| Anticipated Start Date | 2018-05-01 |
| Anticipated End Date | 2022-01-01 |
Participating Hospitals
| Hospital | Ashford Cancer Centre Research |
|---|---|
| Clinical Trial Coordinator | Sue Yeend |
| syeend@adelaidecancercentre.com.au | |
| Phone | 08 8292 2240 |
| Principal Investigator | Dr Sarwan Bishnoi |
| Recruitment Status | Recruiting |